Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer DiseaseEdmond Teng, Carlo de Lena, Sharon Cohen et al.|JAMA Neurology|2022Cited by 188
Identification of longitudinally dynamic biomarkers in Alzheimer’s disease cerebrospinal fluid by targeted proteomicsKristin R. Wildsmith, Lee Honigberg|Molecular Neurodegeneration|2014Cited by 150
Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathologyKaj Blennow, Kina Höglund, Chun Chen et al.|Brain|2019Cited by 106
Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: LaurietCecília Monteiro, William Alvin McElveen, Balázs István Tóth et al.|Neurology|2023Cited by 104
Cross-sectional associations between [18F]GTP1 tau PET and cognition in Alzheimer's diseaseEdmond Teng, Robby M. Weimer, Michael E. Ward et al.|Neurobiology of Aging|2019Cited by 46